ライフサイエンスコーパス: cote

1 y with the outer coat morphogenetic protein, CotE.

2 at is dependent on the morphogenetic protein CotE.

3 in coat surface morphology: CotA, CotB, and CotE.

4 -amino-acid region in the N-terminal half of CotE.

5 ys, including VSe(2)/WSe(2), NiTe(2)/WSe(2), CoTe(2)/WSe(2), NbTe(2)/WSe(2), VS(2)/WSe(2), VSe(2)/MoS

6 high-temperature spin dynamics of Ba(2)La(2)CoTe(2)O(12) (BLCTO): a Co(2+)-based J(eff) = 1/2 TLAF t

7 CoTe(6)O(13) embodies an excellent opportunity for the s

8 (2+), indicating that the magnetic moment in CoTe(6)O(13) has a significant orbital contribution.

9 king advantage of a single crystal sample of CoTe(6)O(13) with an R-3 space group and a Co(2+) triang

10 Key to this is CotE, a protein displayed on the spore surface and carry

11 pores of a strain with mutations in both the cotE and gerE genes, which encode proteins involved in c

12 changes in the C-terminal 23 amino acids of CotE and in the remainder of the protein have different

13 dependent on the coat morphogenetic proteins CotE and SpoIVA.

14 suggest that: (i) most interactions between CotE and the coat proteins assembled under CotE control

15 See also the editorial by Cotes and Jacobs in this issue.

16 expression of morphogenetic proteins SpoIVA, CotE, and SpoVID.

17 ion of three morphogenetic proteins: SpoIVA, CotE, and SpoVID.

18 A 181-amino-acid coat protein called CotE assembles into the coat early in spore formation an

19 D that is essential for the interaction with CotE but dispensable for the interaction with SafA.

20 sembled under CotE control take place at the CotE C-terminus; (ii) an internal region of CotE connect

21 To understand how CotE carries out its role in coat morphogenesis, we subj

22 CotE C-terminus; (ii) an internal region of CotE connects it with the forespore surface; and (iii) i

23 n CotE and the coat proteins assembled under CotE control take place at the CotE C-terminus; (ii) an

24 B. subtilis coat proteins (CotY, CotE, CotV and CotW) expressed in Escherichia coli can a

25 RR 1.04), Zimbabwe (352; 260; RR 1.05), and Cote d'Ivoire (125; 322; RR 1.06).

26 ions, the Republic of South Africa (RSA) and Cote d'Ivoire (CI).

27 untries: Burkina Faso (January-August 2013), Cote d'Ivoire (March 2015-February 2016), The Gambia (Ju

28 of bDNA analysis of human blood samples from Cote d'Ivoire (n = 50) showed excellent agreement with t

29 ce = 2.2%; 1,000 patients treated/year), and Cote d'Ivoire (prevalence = 3%; 150 patients treated/yea

30 1.7-9.2) in Mongolia to 28.3% (13.2-49.8) in Cote d'Ivoire among males.

31 w-borne hantavirus infections in humans from Cote d'Ivoire and Gabon.

32 ces of antepartum depression in mothers from Cote d'Ivoire and Ghana were 28.3% and 26.3%, respective

33 y, hybrids of crosses between genotypes from Cote d'Ivoire and Nigeria produce CPO with exceptionally

34 Genotypes from Benin, Cote d'Ivoire and Nigeria were characterized by high car

35 d of Bioko (in Equatorial Guinea), Cameroon, Cote d'Ivoire and Sierra Leone.

36 ost-effective, and should become standard in Cote d'Ivoire and similar settings.

37 ipe fruit pulp from 20 angiosperm species in Cote d'Ivoire and Uganda contained an average value of 0

38 molecular epidemiology of HIV-1 CRF02_AG in Cote d'Ivoire and West Africa, which could be important

39 nes, we show that the ebolaviruses Zaire and Cote d'Ivoire are strongly dependent on cathepsin B, whi

40 Using cocoa cultivation and exports in Cote d'Ivoire as an example, we present a novel framewor

41 gs suggest the Illizi Basin and the Offshore Cote d'Ivoire Basin could be the most favorable for inve

42 y of the urban populations in The Gambia and Cote d'Ivoire became especially clear during the 2007-20

43 ingle blind, randomized, controlled trial in Cote d'Ivoire between June and August 2017.

44 om surveys undertaken in four communities in Cote d'Ivoire between March, 1997, and September, 2010.

45 al with 40 village-level clusters in central Cote d'Ivoire between Sept 26, 2016, and April 10, 2019.

46 iological characteristics of PBM observed in Cote d'Ivoire during 2010-2016.

47 use events filmed in the Tai National Park, Cote d'Ivoire during the chimpanzee attempts to retrieve

48 bolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MAR

49 rt from the World Health Organization (WHO), Cote d'Ivoire has implemented pediatric bacterial mening

50 tance to major public health insecticides in Cote d'Ivoire has intensified and now threatens the long

51 ms in wild Anopheles coluzzii from Southeast Cote d'Ivoire in 2019.

52 s in wild Anopheles coluzzii from South-East Cote d'Ivoire in 2019.

53 Chimpanzees from the Tai forest of Cote d'Ivoire produce unintentional flaked stone assembl

54 ere were 654 mother/child dyads in Ghana and Cote d'Ivoire that were enrolled in a prospective birth

55 % CI 3.1-3.3) cases per 10 000 population in Cote d'Ivoire to 26.9 (23.5-30.7) cases per 10 000 popul

56 Populations from Cote d'Ivoire were distinguished from other origins by t

57 with Wuchereria bancrofti microfilaremia in Cote d'Ivoire were randomized to receive a single dose o

58 ofti microfilaremia in Agboville district of Cote d'Ivoire were randomized to receive either a single

59 toes sampled along a disturbance gradient in Cote d'Ivoire were tested by generic RT-PCR assays estab

60 eatment strategies for a cohort of adults in Cote d'Ivoire who were infected with the human immunodef

61 ntrolled dose-finding trial was conducted in Cote d'Ivoire with the aim of recruiting 120 preschool-a

62 We assessed cost-effectiveness relative to Cote d'Ivoire's 2013 per capita GDP ($1500).

63 unts for ~44% of the biodiversity impacts in Cote d'Ivoire's cocoa cultivation areas, with >90% attri

64 d 12 months postpartum were 11.8% and 16.1% (Cote d'Ivoire) and 8.9% and 7.2% (Ghana).

65 ountries within the lowest HDI category (eg, COte d'Ivoire) had a maximum 3-year net survival of 54.6

66 ica (SSA) and one in North America: Abidjan (Cote d'Ivoire), Accra (Ghana), Addis Ababa (Ethiopia), a

67 ncer registries in Cotonou (Benin), Abidjan (COte d'Ivoire), Addis Ababa (Ethiopia), Eldoret and Nair

68 to be 3% of gross domestic product (GDP) for Cote d'Ivoire, 0.4% for Malawi, and 0.7% for Senegal.

69 tions to overall SDG performance were 7% for Cote d'Ivoire, 0.7% for Malawi, and 2% for Senegal.

70 to 1.3 percentage points (90% UI 0.8-1.9) in Cote d'Ivoire, 10.6 percentage points (5.3-16.8) in Sene

71 avirus surveillance projects in Cameroon and Cote d'Ivoire, 2 fecal samples collected from 2 children

72 al [UI] 500-900) additional HIV diagnoses in Cote d'Ivoire, 500 (300-900) in Mali, and 300 (50-700) i

73 ulture and a wet tropical forest in southern Cote d'Ivoire, a region of present-day rainforest.

74 chimpanzee (Pan troglodytes verus) sites in Cote d'Ivoire, aged between 4.3 and 1.3 thousand years a

75 pared with existing healthcare activities in Cote d'Ivoire, and is similarly cost-effective to other

76 ies of SDG strategies undertaken in Senegal, Cote d'Ivoire, and Malawi.

77 The rice sectors in The Gambia, Cote d'Ivoire, and Mali are scrutinized as well as cotto

78 4 different species are known: Zaire, Sudan, Cote d'Ivoire, and Reston ebolavirus.

79 e in Kenya and 2 sites each in Burkina Faso, Cote d'Ivoire, and Uganda.

80 rom the other pathogenic subtypes, Sudan and Cote d'Ivoire, as well as from Reston, a strain thought

81 tries in sub-Saharan Africa (Benin, Burundi, Cote d'Ivoire, Democratic Republic of the Congo, Ghana,

82 erapy programmes and tuberculosis clinics in Cote d'Ivoire, Democratic Republic of the Congo, Kenya,

83 This multicentre cohort study was done in Cote d'Ivoire, Democratic Republic of the Congo, Kenya,

84 before 2008, and 16 after 2008) in Cameroon, Cote d'Ivoire, DR Congo, Ethiopia, Guinea, Kenya, Lesoth

85 Five (20%) had no clear pattern (Cote d'Ivoire, DR Congo, Madagascar, Mauritius, and Rwan

86 nosis based on two serial tests in Cameroon, Cote d'Ivoire, Eswatini, Haiti, Kenya, Lesotho, Malawi,

87 n countries in Africa (Angola, Burkina Faso, Cote d'Ivoire, Ethiopia, Senegal, Sudan, and Zimbabwe),

88 In Thailand and Cote d'Ivoire, focusing treatment only on F3-F4 patients

89 e data from Benin, Burkina Faso, Cabo Verde, Cote d'Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Lib

90 ducted a prospective evaluation in Cameroon, Cote d'Ivoire, Ghana, and the Republic of the Congo to d

91 meningitis belt (Benin, Burkina Faso, Chad, Cote d'Ivoire, Ghana, Mali, Niger, Nigeria, and Togo) co

92 eforestation: South American soy, cocoa from Cote d'Ivoire, Indonesian palm oil, and Brazilian live c

93 nical outcomes in eight countries (Cameroon, Cote d'Ivoire, Kenya, Lesotho, Mozambique, Rwanda, Swazi

94 Influenza Centers from 5 countries-Cameroon, Cote d'Ivoire, Madagascar, Niger, and Senegal--collected

95 IV epidemiological, and intervention data in Cote d'Ivoire, Mali, and Senegal separately during 1980-

96 ho have sex with men, and their partners, in Cote d'Ivoire, Mali, and Senegal.

97 event-driven or daily PrEP in Burkina Faso, Cote d'Ivoire, Mali, and Togo.

98 table HPV infections in MSM in Burkina Faso, Cote d'Ivoire, Mali, and Togo.

99 , Chad, Democratic Republic of Congo, Ghana, Cote d'Ivoire, Mali, Niger, Nigeria, Togo).

100 o 2 years of age in 4 high-burden countries: Cote d'Ivoire, Mozambique, Uganda, and Zimbabwe.

101 y ~one-third of households in six countries (Cote d'Ivoire, Nigeria, Malawi, Senegal, Tanzania, and U

102 various treatment-as-prevention scenarios in Cote d'Ivoire, one of the countries with the highest HIV

103 obust across the four diverse communities in Cote d'Ivoire, only one of which would have received ann

104 c compartmental model of HIV transmission in Cote d'Ivoire, parameterised and fitted to country-speci

105 n African trypanosomiasis foci in Guinea and Cote d'Ivoire, respectively.

106 s-sectional study in Burkina Faso, Cameroon, Cote d'Ivoire, Senegal, Togo, Thailand, and Vietnam to a

107 ild-born captive chimpanzees in Cameroon and Cote d'Ivoire, shows that P. reichenowi is a geographica

108 o started ART in four scale-up programmes in Cote d'Ivoire, South Africa, and Malawi from 2004 to 200

109 ent core cocoa production areas in Ghana and Cote d'Ivoire, suggesting a potential mismatch for the o

110 done in 25 sites in Burkina Faso, Cameroon, Cote d'Ivoire, The Gambia, Guinea-Bissau, Nigeria, Seneg

111 In Cote d'Ivoire, the most prevalent HIV-1 subtype is CRF02

112 um infections in the city of Bouake, Central Cote d'Ivoire, to compare the performance of three tests

113 el insecticide-based intervention in central Cote d'Ivoire, we assessed resistance and its underlying

114 trial (CRT) of the EaveTube intervention in Cote d'Ivoire, we investigated the residual efficacy of

115 In this cluster randomised trial in Abidjan, Cote d'Ivoire, we randomly assigned communal housing com

116 ern chimpanzees, from the Tai National Park, Cote d'Ivoire, we tested whether chimpanzees make decisi

117 l Park, Guinea-Bissau and Tai National Park, Cote d'Ivoire, West Africa.

118 lants throughout the canopy (0.3 to 42 m) in Cote d'Ivoire, West Africa.

119 d current and novel monitoring strategies in Cote d'Ivoire, West Africa.

120 zees (Pan troglodytes) in Tai National Park, Cote d'Ivoire, where adult social play and collective ac

121 din in areas of high resistance intensity in Cote d'Ivoire.

122 lar low efficacy in treating trichuriasis in Cote d'Ivoire.

123 l meningitis among children aged <5 years in Cote d'Ivoire.

124 ced activity of the combination therapies in Cote d'Ivoire.

125 tions of Anopheles gambiae s.l. in Tiassale, Cote d'Ivoire.

126 public of Congo and the Tai chimpanzees from Cote d'Ivoire.

127 t Anopheles gambiae s.l. from experiments in Cote d'Ivoire.

128 ficacy, with therapeutic underperformance in Cote d'Ivoire.

129 .3% (3.0-8.9) in Mali, and 1.6% (1.0-2.4) in Cote d'Ivoire.

130 emains a major disease affecting children in Cote d'Ivoire.

131 din in areas of high resistance intensity in Cote d'Ivoire.

132 rgeted strategies to reduce malaria in urban Cote d'Ivoire.

133 outside (Abidjan) of the meningitis belt of Cote d'Ivoire.

134 s previously enrolled in the STATIS trial in Cote d'Ivoire.

135 zees (ages 0-10 years) in Tai National Park, Cote d'Ivoire.

136 mosis among individuals with advanced HIV in Cote d'Ivoire.

137 an alternative to albendazole monotherapy in Cote d'Ivoire.

138 tobium in a seasonal transmission setting of Cote d'Ivoire.

139 ctive and less costly than CD4 monitoring in Cote d'Ivoire.

140 sus ST0 in Thailand, and 13.1% versus SC0 in Cote d'Ivoire.

141 to the entire community in four settings in Cote d'Ivoire.

142 surveillance system located in south-central Cote d'Ivoire.

143 Pan troglodytes verus) in Tai National Park, Cote d'Ivoire.

144 s conducted in the Taabo area, south-central Cote d'Ivoire.

145 2 research cohorts of HIV-infected adults in Cote d'Ivoire.

146 or HIV-1/2-infected blood donors in Abidjan, Cote d'Ivoire.

147 e-ranging sooty mangabeys in the Tai Forest, Cote d'Ivoire.

148 man immunodeficiency virus type 1 (HIV-1) in Cote d'Ivoire.

149 les, and 16 confirmed HIV-2 samples from the Cote d'Ivoire.

150 [for Port Harcourt in Nigeria and Abidjan in Cote D'Ivoire] were obtained from the HadCRUT-4 project

151 ission, Registre des Hemopathies Malignes de Cote d'Or, and French Agence Nationale de la Recherche.

152 n 18-amino-acid stretch in the N-terminus of CotE direct the formation of CotE multimers, most probab

153 c mutants, we show in vitro and ex vivo that CotE enables binding of spores to mucus by direct intera

154 l stages of coat assembly a protein known as CotE forms a ring around the forespore.

155 However, the cotE gerE spores did retain a thin layer of insoluble co

156 In Bacillus subtilis, a coat protein called CotE guides the assembly of a major subset of coat prote

157 However, CotE has only a modest role in coat protein assembly, in

158 One of these, cotE, has a striking function in B. anthracis: it guides

159 simple disease-specific comorbidities index (COTE) helps assess mortality risk in patients with COPD.

160 dictor of mortality and explored whether the COTE index added predictive information when used with t

161 We tested the COTE index as predictor of mortality and explored whethe

162 Increases in the COTE index were associated with an increased risk of dea

163 icted mortality and were integrated into the COTE index.

164 In animal models of CDI, we show that when CotE is absent, both colonization and virulence were mar

165 pore surface; and (iii) interactions between CotE molecules depend on residues within an 18-amino-aci

166 e N-terminus of CotE direct the formation of CotE multimers, most probably homooligomers.

167 cotE mutant spores are fully virulent in animal models,

168 for infection, at least in the context of a cotE mutation.

169 of lacZ to the sporulation loci, spollA and cotE, of Bacillus subtilis were introduced into S. ureae

170 d studied the effects of altered versions of CotE on coat formation.

171 ding the subsequent positioning of a ring of CotE protein about 75 nm from the forespore surface.

172 beta-type small, acid-soluble protein or the CotE protein responsible for assembly of much spore coat

173 epitope, between amino acids 178 and 179 of CotE, reduced or prevented the assembly of several spore

174 t functions to maintain the integrity of the CotE ring and to anchor the nascent coat to the underlyi

175 , SpoVID, is required for maintenance of the CotE ring during the later stages, when most of proteins

176 A landmark study published in PNAS [Cote S, House J, Willer R (2015) Proc Natl Acad Sci USA

177 A COTE score of greater than or equal to 4 points increase

178 e the following: (i) the reason decoated and cotE spores germinate poorly with dipicolinic acid is th

179 ng spore germination, and was not present in cotE spores in which the spore coat is aberrant.

180 We have used a series of mutant alleles of cotE to identify regions involved in outer coat protein

181 cid internal region involved in targeting of CotE to the forespore.

182 ter coat but did not prevent localization of CotE to the forespore.

183 idity index (COPD specific comorbidity test [COTE]) was constructed based on the comorbidities that i

184 Further, increases in the BODE and COTE were independently associated with increased risk o